A protein pulled from rattlesnake blood has produced antivenom mixtures about ten times more potent than the sheep-derived antivenom currently used to treat pit viper bites, according to research led by University of Maryland biologist Sean B. Carroll. The protein, called FETUA-3, was first identified in Carroll’s lab in 2022, and new laboratory tests show it can neutralize the lethal effects of venom from the western diamondback rattlesnake and several related viper species. The finding points toward an antivenom built from a snake’s own natural defenses rather than from another animal’s immune system.
A Resistance Anecdotally Known for a Century
Scientists have long known, mostly from anecdote, that vipers tend to be resistant to their own venom, but for decades nobody could say what was actually circulating in a rattlesnake’s blood to protect it. Carroll’s lab closed that gap in 2022 by isolating FETUA-3, a protein capable of blocking the metalloproteinase toxins that account for much of rattlesnake venom’s damage, the enzymes responsible for breaking down blood vessels and tissue at a bite site and causing the swelling and internal bleeding that make untreated bites so dangerous. Carroll called the discovery “one of those great stories when nature has already solved a problem” researchers had been chasing for decades, a description that frames the work as recovery rather than invention: the rattlesnake had already engineered a defense against its own weapon, and the research mainly had to find and isolate it.
New laboratory testing described in the University of Maryland’s own account of the research found that combinations of FETUA-3 with other toxin-blocking proteins from rattlesnake blood proved about ten times more potent than a current commercial, sheep-derived rattlesnake antivenom, and provided broad protection against venom from multiple viper species rather than only the western diamondback. The results appear in the Proceedings of the National Academy of Sciences, with Carroll’s University of Maryland co-authors Fiona Ukken and Yetunde Ayinuola and Texas A&M University-Kingsville researcher Elda Sánchez.
A Production Method Largely Unchanged for a Century
Commercial antivenom is still made largely the way it has been for more than a hundred years: small doses of venom are injected into a sheep or horse, and the antibodies that animal’s immune system produces are collected from its blood and purified into the treatment given to snakebite patients. That method works, but the resulting serum carries foreign antibodies that can trigger allergic reactions in some patients and generally has to be matched closely to the species responsible for the bite. Toxin-blocking proteins taken directly from a viper’s own blood sidestepped both problems in early testing, since they come from the same biological system the venom evolved to defeat, and mixtures built from them completely neutralized lethal venom doses in the laboratory, according to the findings summarized alongside the PNAS paper.
Carroll described the remaining work as mostly a matter of formulation. “The ingredients are there,” he said, adding that his team now simply has to keep testing different combinations to see which mixtures protect most reliably against which venoms.
A Global Toll of Up to 137,880 Deaths a Year
The stakes are set by the World Health Organization, which estimates that around 81,410 to 137,880 people die each year from snakebites worldwide, with roughly three times as many surviving with amputations or other permanent disabilities. That burden falls hardest on agricultural workers and children across Africa, Asia and Latin America, populations for whom access to any antivenom, let alone a matched one, is often the limiting factor rather than the drug’s potency, since clinics in remote farming regions frequently run short of stock or stock the wrong species-specific serum for a local bite. A more powerful, more broadly protective antivenom would not by itself solve supply and distribution gaps, but it would let a single vial cover more species and stretch further per dose, which matters most in the rural clinics furthest from a hospital.
From Veterinary Trials to Human Treatment
Carroll expects the first commercial use of the protein-based approach to arrive in veterinary medicine, where regulatory paths are shorter, well before any version reaches human patients. He described the team as “getting remarkably close to having effective solutions for the three major toxin families in vipers,” calling nature-based recombinant antivenoms “within reach” rather than a distant goal.
Scaling the approach to meet demand, he said, is a question of manufacturing volume rather than biology: enough of the protein mixture could in principle be produced to fill “train cars,” aimed at what he calls “a massive global health problem” that has changed little in the century since researchers first noticed a rattlesnake shrugging off its own venom and simply filed the observation away as a curiosity rather than a lead.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- A handful of car engines are so tough mechanics say they almost never wear out
- The NSA is again telling phone owners to switch off one location setting
- Supplements now rank as the fifth-leading cause of death from liver disease.
- Herbal supplements are landing Americans in the hospital with liver damage, doctors warn
